MDT-AP-0550
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 96
- os_event
- false
- age_years
- 5
- sex
- M
- new_clusters
- C3
- umap1_2d
- 5.750098972
- umap2_2d
- 3.312838468
- umap1_3d
- 2.629481137
- umap2_3d
- -2.709636137
- umap3_3d
- -2.410582385
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.230
- WNT_BETA_CATENIN_SIGNALING+0.200
- DNA_REPAIR+0.140
- HEME_METABOLISM+0.110
- PI3K_AKT_MTOR_SIGNALING+0.100
- SPERMATOGENESIS+0.100
- PROTEIN_SECRETION+0.040
- ADIPOGENESIS+0.030
- PEROXISOME+0.020
- KRAS_SIGNALING_DN+0.010
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- ALLOGRAFT_REJECTION-0.380
- ANGIOGENESIS-0.370
- INFLAMMATORY_RESPONSE-0.320
- COMPLEMENT-0.310
- KRAS_SIGNALING_UP-0.290
- INTERFERON_ALPHA_RESPONSE-0.280
- MYC_TARGETS_V1-0.280
- HEDGEHOG_SIGNALING-0.270
- COAGULATION-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0038 | Med | Medulloblastoma | 0.956 |
| 2 | MDT-AP-1357 | Med | Medulloblastoma | 0.916 |
| 3 | MDT-AP-0578 | Med | Medulloblastoma | 0.908 |
| 4 | MDT-AP-1341 | Med | Medulloblastoma | 0.884 |
| 5 | MDT-AP-1345 | Med | Medulloblastoma | 0.884 |
| 6 | MDT-AP-1354 | Med | Medulloblastoma | 0.883 |
| 7 | MDT-AP-0350 | Med | Medulloblastoma | 0.881 |
| 8 | MDT-AP-1134 | Med | Medulloblastoma | 0.879 |
| 9 | TCGA-S3-AA11-01A-31R-A41B-07 | — | B | 0.875 |
| 10 | SRR607967 | GTEX | — | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.040 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |